BioSpace News Archive

Integrated Biosciences in collaboration with researchers at the University of California Santa Barbara, today announced a drug discovery platform that enables precise control of the integrated stress response (ISR), a biological pathway that is activated by cells in response to a wide variety of pathological and aging-associated conditions.

Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2023 after the stock market closes on Tuesday, Aug. 15.

Panbela Therapeutics, Inc. today announced it has divested certain assets in its eflornithine pediatric neuroblastoma program to US WorldMeds ® 1 (USWM), a Kentucky-based specialty pharmaceutical company.

COUR Pharmaceuticals today announced the appointment of Dannielle Appelhans as Chief Operating Officer, effective immediately.

Genprex, Inc. today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale and issuance of 7,425,744 shares of the Company’s common stock and warrants to purchase up to 7,425,744 shares of common stock at a combined offering price of $1.01 per share.

Hoth Therapeutics, Inc. today announced that it has received approval from the Food & Drug Administration (“FDA”) for a protocol change in its Phase 2a clinical trial of HT-001.

DermTech, Inc. today announced a favorable coverage policy with a Blues plan in Michigan.

VBI Vaccines Announces PreHevbri ® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults.

SURGE Therapeutics announced today the completion of a $32 million Series B financing.

Zymeworks Inc. today announced that management will report its second quarter 2023 financial results after market close on August 10, 2023.